Why the study?
Do immunomodulatory drugs affect the development and progression of atherosclerosis?
Do immunomodulatory drugs affect the development and progression of atherosclerosis?
This review highlights the potential of targeting inflammatory and cytokine pathways with immunomodulatory drugs to treat or prevent atherosclerosis.
Answers are grounded in this paper and cite their sources.
Cautions against changing practice based on this hypothesis; leaves open whether immunomodulatory drugs improve atherosclerosis outcomes in trials.
Inflammation and cytokine pathways are crucial for the development and progression of atherosclerotic lesions. In this review, the hypothesis that immunomodulatory drugs provide a possible therapeutic modality for cardiovascular disease is evaluated. Therefore, after a short overview of the specific inflammatory pathways involved in atherosclerosis, literature on the effect of several immunomodulatory drugs, such as nonsteroidal anti-inflammatory drugs, specific cyclooxygenase inhibitors and immunosuppressive drugs, used currently in the prevention of rejection after organ transplant, on the development and progression of atherosclerosis is reviewed. In addition, the pleiotropic immunomodulatory effect of two established cardiovascular drugs (angiotensin-converting enzyme inhibitors and statins) is discussed.
No takes yet. Share an insight, caveat, or question.
Heeneman et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: